Responses
Clinical and epidemiological research
Extended report
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
Compose a Response to This Article
Other responses
No responses have been published for this article.